{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd\n",
    "qa_data_path = \"/data_x/guro/guro_eval.jsonl\"\n",
    "qa_data = pd.read_json(qa_data_path, lines=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>query</th>\n",
       "      <th>context</th>\n",
       "      <th>answer</th>\n",
       "      <th>catagory</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>What is HER2-positive breast cancer?</td>\n",
       "      <td>HER2 positivity accounts for about 15–20% of b...</td>\n",
       "      <td>HER2-positive breast cancer accounts for about...</td>\n",
       "      <td>HER2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>How is HER2-positive status determined in brea...</td>\n",
       "      <td>Currently, immunohistochemistry (IHC), fluores...</td>\n",
       "      <td>To diagnose HER2-positive breast cancer, sever...</td>\n",
       "      <td>HER2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Describe the mechanism of action of HER2 in br...</td>\n",
       "      <td>Normal tissues have a low complement of HER2 m...</td>\n",
       "      <td>HER2 can form heterodimers with other members ...</td>\n",
       "      <td>HER2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>What are the prognosis of HER2-positive breast...</td>\n",
       "      <td>HER2-positive breast cancer is an aggressive t...</td>\n",
       "      <td>HER2-positive tumors were more likely to be no...</td>\n",
       "      <td>HER2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>What are the first-line treatment options for ...</td>\n",
       "      <td>For patients with disease relapse 1 year after...</td>\n",
       "      <td>First-line treatment options for HER2-positive...</td>\n",
       "      <td>HER2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>93</th>\n",
       "      <td>What is the lifetime risk of developing breast...</td>\n",
       "      <td>the cumulative risk of breast cancer in BRCA c...</td>\n",
       "      <td>The estimated penetrance of breast cancer to a...</td>\n",
       "      <td>Hereditary Breast Cancer</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>94</th>\n",
       "      <td>What are clinical criteria that would suggest ...</td>\n",
       "      <td>An ASCO–Society of Surgical Oncology (SSO) pan...</td>\n",
       "      <td>BRCA1/2 mutation testing should be offered to ...</td>\n",
       "      <td>Hereditary Breast Cancer</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>95</th>\n",
       "      <td>what features are commonly seen in patients wi...</td>\n",
       "      <td></td>\n",
       "      <td>BRCA1/2-associated breast cancers typically oc...</td>\n",
       "      <td>Hereditary Breast Cancer</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>96</th>\n",
       "      <td>Outline the preventive strategies for individu...</td>\n",
       "      <td>The guidelines will focus on cancer prevention...</td>\n",
       "      <td>Limited data are available about the use of se...</td>\n",
       "      <td>Hereditary Breast Cancer</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>97</th>\n",
       "      <td>What is the role of PARP inhibitors in the tre...</td>\n",
       "      <td>Poly-adenosine diphosphate ribose polymerase (...</td>\n",
       "      <td>Poly-adenosine diphosphate ribose polymerase (...</td>\n",
       "      <td>Hereditary Breast Cancer</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>98 rows × 4 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                query  \\\n",
       "0                What is HER2-positive breast cancer?   \n",
       "1   How is HER2-positive status determined in brea...   \n",
       "2   Describe the mechanism of action of HER2 in br...   \n",
       "3   What are the prognosis of HER2-positive breast...   \n",
       "4   What are the first-line treatment options for ...   \n",
       "..                                                ...   \n",
       "93  What is the lifetime risk of developing breast...   \n",
       "94  What are clinical criteria that would suggest ...   \n",
       "95  what features are commonly seen in patients wi...   \n",
       "96  Outline the preventive strategies for individu...   \n",
       "97  What is the role of PARP inhibitors in the tre...   \n",
       "\n",
       "                                              context  \\\n",
       "0   HER2 positivity accounts for about 15–20% of b...   \n",
       "1   Currently, immunohistochemistry (IHC), fluores...   \n",
       "2   Normal tissues have a low complement of HER2 m...   \n",
       "3   HER2-positive breast cancer is an aggressive t...   \n",
       "4   For patients with disease relapse 1 year after...   \n",
       "..                                                ...   \n",
       "93  the cumulative risk of breast cancer in BRCA c...   \n",
       "94  An ASCO–Society of Surgical Oncology (SSO) pan...   \n",
       "95                                                      \n",
       "96  The guidelines will focus on cancer prevention...   \n",
       "97  Poly-adenosine diphosphate ribose polymerase (...   \n",
       "\n",
       "                                               answer  \\\n",
       "0   HER2-positive breast cancer accounts for about...   \n",
       "1   To diagnose HER2-positive breast cancer, sever...   \n",
       "2   HER2 can form heterodimers with other members ...   \n",
       "3   HER2-positive tumors were more likely to be no...   \n",
       "4   First-line treatment options for HER2-positive...   \n",
       "..                                                ...   \n",
       "93  The estimated penetrance of breast cancer to a...   \n",
       "94  BRCA1/2 mutation testing should be offered to ...   \n",
       "95  BRCA1/2-associated breast cancers typically oc...   \n",
       "96  Limited data are available about the use of se...   \n",
       "97  Poly-adenosine diphosphate ribose polymerase (...   \n",
       "\n",
       "                    catagory  \n",
       "0                       HER2  \n",
       "1                       HER2  \n",
       "2                       HER2  \n",
       "3                       HER2  \n",
       "4                       HER2  \n",
       "..                       ...  \n",
       "93  Hereditary Breast Cancer  \n",
       "94  Hereditary Breast Cancer  \n",
       "95  Hereditary Breast Cancer  \n",
       "96  Hereditary Breast Cancer  \n",
       "97  Hereditary Breast Cancer  \n",
       "\n",
       "[98 rows x 4 columns]"
      ]
     },
     "execution_count": 2,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "qa_data"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "qa = []\n",
    "\n",
    "for index, data in enumerate(qa_data[\"query\"]):\n",
    "    qa.append({\n",
    "        \"qid\": str(index),\n",
    "        \"query\": data,\n",
    "        \"generation_gt\": [qa_data[\"answer\"][index]],\n",
    "        \"retrieval_gt\": [[\"None\"]]\n",
    "    })\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [],
   "source": [
    "save_dir = \"/data_x/guro/DATA/ASCO_RAW\"\n",
    "\n",
    "qa_df = pd.DataFrame(qa)\n",
    "qa_df.to_parquet(save_dir + \"/qa.parquet\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "autorag",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.11.10"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
